Literature DB >> 21550980

Characterization of prefibrillar Tau oligomers in vitro and in Alzheimer disease.

Kristina R Patterson1, Christine Remmers, Yifan Fu, Sarah Brooker, Nicholas M Kanaan, Laurel Vana, Sarah Ward, Juan F Reyes, Keith Philibert, Marc J Glucksman, Lester I Binder.   

Abstract

Neurofibrillary tangles, composed of insoluble aggregates of the microtubule-associated protein Tau, are a pathological hallmark of Alzheimer disease (AD) and other tauopathies. However, recent evidence indicates that neuronal dysfunction precedes the formation of these insoluble fibrillar deposits, suggesting that earlier prefibrillar Tau aggregates may be neurotoxic. To determine the composition of these aggregates, we have employed a photochemical cross-linking technique to examine intermolecular interactions of full-length Tau in vitro. Using this method, we demonstrate that dimerization is an early event in the Tau aggregation process and that these dimers self-associate to form larger oligomeric aggregates. Moreover, using these stabilized Tau aggregates as immunogens, we generated a monoclonal antibody that selectively recognizes Tau dimers and higher order oligomeric aggregates but shows little reactivity to Tau filaments in vitro. Immunostaining indicates that these dimers/oligomers are markedly elevated in AD, appearing in early pathological inclusions such as neuropil threads and pretangle neurons as well as colocalizing with other early markers of Tau pathogenesis. Taken as a whole, the work presented herein demonstrates the existence of alternative Tau aggregates that precede formation of fibrillar Tau pathologies and raises the possibility that these hierarchical oligomeric forms of Tau may contribute to neurodegeneration.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21550980      PMCID: PMC3123074          DOI: 10.1074/jbc.M111.237974

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  85 in total

1.  In vitro polymerization of tau protein monitored by laser light scattering: method and application to the study of FTDP-17 mutants.

Authors:  T C Gamblin; M E King; H Dawson; M P Vitek; J Kuret; R W Berry; L I Binder
Journal:  Biochemistry       Date:  2000-05-23       Impact factor: 3.162

2.  Assembly of tau protein into Alzheimer paired helical filaments depends on a local sequence motif ((306)VQIVYK(311)) forming beta structure.

Authors:  M von Bergen; P Friedhoff; J Biernat; J Heberle; E M Mandelkow; E Mandelkow
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-09       Impact factor: 11.205

Review 3.  Neurodegenerative tauopathies.

Authors:  V M Lee; M Goedert; J Q Trojanowski
Journal:  Annu Rev Neurosci       Date:  2001       Impact factor: 12.449

4.  Transglutaminase bonds in neurofibrillary tangles and paired helical filament tau early in Alzheimer's disease.

Authors:  Steven M Singer; Gina M Zainelli; Maryam A Norlund; John M Lee; Nancy A Muma
Journal:  Neurochem Int       Date:  2002-01       Impact factor: 3.921

5.  Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein.

Authors:  J Lewis; E McGowan; J Rockwood; H Melrose; P Nacharaju; M Van Slegtenhorst; K Gwinn-Hardy; M Paul Murphy; M Baker; X Yu; K Duff; J Hardy; A Corral; W L Lin; S H Yen; D W Dickson; P Davies; M Hutton
Journal:  Nat Genet       Date:  2000-08       Impact factor: 38.330

6.  Tauopathy in Drosophila: neurodegeneration without neurofibrillary tangles.

Authors:  C W Wittmann; M F Wszolek; J M Shulman; P M Salvaterra; J Lewis; M Hutton; M B Feany
Journal:  Science       Date:  2001-06-14       Impact factor: 47.728

7.  Frequency of tau gene mutations in familial and sporadic cases of non-Alzheimer dementia.

Authors:  P Poorkaj; M Grossman; E Steinbart; H Payami; A Sadovnick; D Nochlin; T Tabira; J Q Trojanowski; S Borson; D Galasko; S Reich; B Quinn; G Schellenberg; T D Bird
Journal:  Arch Neurol       Date:  2001-03

8.  Tau filament formation in transgenic mice expressing P301L tau.

Authors:  J Götz; F Chen; R Barmettler; R M Nitsch
Journal:  J Biol Chem       Date:  2001-01-05       Impact factor: 5.157

9.  Oxidative regulation of fatty acid-induced tau polymerization.

Authors:  T C Gamblin; M E King; J Kuret; R W Berry; L I Binder
Journal:  Biochemistry       Date:  2000-11-21       Impact factor: 3.162

10.  C-terminal inhibition of tau assembly in vitro and in Alzheimer's disease.

Authors:  A Abraha; N Ghoshal; T C Gamblin; V Cryns; R W Berry; J Kuret; L I Binder
Journal:  J Cell Sci       Date:  2000-11       Impact factor: 5.285

View more
  146 in total

1.  Pre-synaptic C-terminal truncated tau is released from cortical synapses in Alzheimer's disease.

Authors:  Sophie Sokolow; Kristen M Henkins; Tina Bilousova; Bianca Gonzalez; Harry V Vinters; Carol A Miller; Lindsey Cornwell; Wayne W Poon; Karen H Gylys
Journal:  J Neurochem       Date:  2015-01-13       Impact factor: 5.372

Review 2.  Axonal degeneration in Alzheimer's disease: when signaling abnormalities meet the axonal transport system.

Authors:  Nicholas M Kanaan; Gustavo F Pigino; Scott T Brady; Orly Lazarov; Lester I Binder; Gerardo A Morfini
Journal:  Exp Neurol       Date:  2012-06-19       Impact factor: 5.330

3.  Tau Oligomers Derived from Traumatic Brain Injury Cause Cognitive Impairment and Accelerate Onset of Pathology in Htau Mice.

Authors:  Julia Gerson; Diana L Castillo-Carranza; Urmi Sengupta; Riddhi Bodani; Donald S Prough; Douglas S DeWitt; Bridget E Hawkins; Rakez Kayed
Journal:  J Neurotrauma       Date:  2016-04-22       Impact factor: 5.269

4.  Beyond amyloid: getting real about nonamyloid targets in Alzheimer's disease.

Authors:  Karl Herrup; Maria C Carrillo; Dale Schenk; Angela Cacace; Susan Desanti; Robert Fremeau; Ratan Bhat; Marcie Glicksman; Patrick May; Russell Swerdlow; Linda J Van Eldik; Lisa J Bain; Samantha Budd
Journal:  Alzheimers Dement       Date:  2013-07       Impact factor: 21.566

5.  Prefibrillar tau oligomers in mild cognitive impairment and Alzheimer's disease.

Authors:  Elliott J Mufson; Sarah Ward; Lester Binder
Journal:  Neurodegener Dis       Date:  2013-09-11       Impact factor: 2.977

Review 6.  Cellular factors modulating the mechanism of tau protein aggregation.

Authors:  Sarah N Fontaine; Jonathan J Sabbagh; Jeremy Baker; Carlos R Martinez-Licha; April Darling; Chad A Dickey
Journal:  Cell Mol Life Sci       Date:  2015-02-11       Impact factor: 9.261

Review 7.  Tau-mediated synaptic and neuronal dysfunction in neurodegenerative disease.

Authors:  Tara E Tracy; Li Gan
Journal:  Curr Opin Neurobiol       Date:  2018-05-10       Impact factor: 6.627

8.  Analysis of isoform-specific tau aggregates suggests a common toxic mechanism involving similar pathological conformations and axonal transport inhibition.

Authors:  Kristine Cox; Benjamin Combs; Brenda Abdelmesih; Gerardo Morfini; Scott T Brady; Nicholas M Kanaan
Journal:  Neurobiol Aging       Date:  2016-07-29       Impact factor: 4.673

9.  Oligomerization of the microtubule-associated protein tau is mediated by its N-terminal sequences: implications for normal and pathological tau action.

Authors:  H Eric Feinstein; Sarah J Benbow; Nichole E LaPointe; Nirav Patel; Srinivasan Ramachandran; Thanh D Do; Michelle R Gaylord; Noelle E Huskey; Nicolette Dressler; Megan Korff; Brady Quon; Kristi Lazar Cantrell; Michael T Bowers; Ratnesh Lal; Stuart C Feinstein
Journal:  J Neurochem       Date:  2016-04-20       Impact factor: 5.372

10.  Tau and Axonal Transport Misregulation in Tauopathies.

Authors:  Benjamin Combs; Rebecca L Mueller; Gerardo Morfini; Scott T Brady; Nicholas M Kanaan
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.